Clinical TrialsIGC reported positive interim results from its Phase 2 trial for IGC-AD1, showing a significant reduction in agitation compared to placebo in patients with Alzheimer's disease.

Growth OpportunitiesThe company's strategic expansion into the $75 billion wellness industry with the launch of the Holiby brand offers new growth opportunities.

Market PotentialThe large market potential for Alzheimer's treatments presents high rewards despite the risks, given the growing number of Americans affected by the disease.

Bears Say

Market RisksThe large market potential for Alzheimer's disease treatment, due to the absence of a known cure and a growing number of patients, presents high rewards for the risks involved.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

2.37% Insiders

1.42% Mutual Funds

0.10% Other Institutional Investors

95.36% Public Companies and

Individual Investors

Detailed Ownership Overview >

IGC FAQ

What was IGC Pharma’s price range in the past 12 months?

IGC Pharma lowest stock price was $0.25 and its highest was $0.48 in the past 12 months.

What is IGC Pharma’s market cap?

IGC Pharma’s market cap is $33.46M.

When is IGC Pharma’s upcoming earnings report date?

IGC Pharma’s upcoming earnings report date is Aug 06, 2025 which is in 11 days.

How were IGC Pharma’s earnings last quarter?

IGC Pharma released its earnings results on Jun 30, 2025. The company reported -$0.02 earnings per share for the quarter, the consensus estimate of -$0.02 by $0.

Is IGC Pharma overvalued?

According to Wall Street analysts IGC Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does IGC Pharma pay dividends?

IGC Pharma does not currently pay dividends.

What is IGC Pharma’s EPS estimate?

IGC Pharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does IGC Pharma have?

IGC Pharma has 83,891,590 shares outstanding.

What happened to IGC Pharma’s price movement after its last earnings report?

IGC Pharma reported an EPS of -$0.02 in its last earnings report, expectations of -$0.02. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of IGC Pharma?

Currently, no hedge funds are holding shares in IGC

IGC Pharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-104.33%

Trailing 12-Months

Asset Growth

-11.66%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

IGC Pharma

IGC Pharma (IGC) is a biopharmaceutical company engaged in the development and commercialization of innovative therapies for the treatment of debilitating and life-altering medical conditions. The company's core focus is on leveraging its expertise in cannabinoid-based therapies to address unmet needs in areas such as Alzheimer’s disease, chronic pain, and other neurological disorders. IGC Pharma is dedicated to advancing its pipeline of proprietary research compounds and delivering effective solutions that improve patients' quality of life.